Mesoblast Limited vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Mesoblast Limited trades at $16.34 (market cap $2.17B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.65. The key difference: Mesoblast Limited is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| MESO | VNQI | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $50.76 |
52-Week Low | $12.88 | $43.26 |
Enterprise Value | $2.17B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.5, down 0.48% today, with technical indicators showing a bullish trend but neutral oscillators. The ETF provides diversified international real estate exposure across 30+ countries with a low 0.12% expense ratio and a 4.6% dividend yield. Recent news highlights its role as a cost-effective diversifier compared to domestic REIT ETFs, though it has lagged in total returns over the past five years.
The outlook remains cautiously optimistic as global real estate transaction volumes are expected to rise over 10% in 2026 amid stabilizing rates. Key opportunities include international diversification and attractive yield, while risks involve currency fluctuations and slower international market recovery compared to U.S. real estate.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →